Oral Leukoplakia Clinical Trial
Official title:
Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study
The goal of this clinical research study is to learn how Actos (pioglitazone) may affect oral premalignant lesions (OPLs) and/or the risk of mouth cancer. The safety of this drug will also be studied.
PRIMARY OBJECTIVES:
I. To determine the clinical and histologic response of oral premalignant lesions to 24
weeks of therapy with pioglitazone, 45 mg qd, defined as 50% or greater reduction in the sum
of all measured products of perpendicular dimensions of target lesions, or improvement in
the degree of dysplasia or hyperplasia.
SECONDARY OBJECTIVES:
I. To determine the degree of change of putative biomarkers of pioglitazone efficacy
including (but not restricted to) and in order of priority, tissue levels of:
- PPAR gamma,
- cyclin D1 and p21 as indirect measures of pharmacological effect
- TUNEL for apoptosis and Ki-67 for proliferation
- transglutaminase and involucrin as markers of squamous differentiation
- 15-PGDH, loss of heterozygosity (LOH). II. To determine the degree of change of
C-reactive protein (CRP) in plasma. III. To assess tobacco and alcohol use among trial
participants and to examine the relationship of tobacco and alcohol use to treatment
response.
IV. To assess the safety of this agent in this population.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pioglitazone hydrochloride orally (PO) once daily (QD) for 24 weeks.
ARM II: Patients receive placebo PO QD for 24 weeks.
After completion of study treatment, patients are followed up for 2 weeks.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05505539 -
Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
|
Phase 1 | |
Terminated |
NCT00176566 -
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT04712929 -
Candida Associated Cytokines in Oral Leukoplakia
|
||
Completed |
NCT03031899 -
Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
|
||
Terminated |
NCT00571558 -
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
|
Phase 1 | |
Recruiting |
NCT06321003 -
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
|
||
Not yet recruiting |
NCT04732741 -
Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT00369174 -
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT00099021 -
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Not yet recruiting |
NCT05727761 -
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
|
Phase 2 | |
Active, not recruiting |
NCT02581137 -
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
|
Phase 2 | |
Recruiting |
NCT05942794 -
Identification of Oral Lesions Through an Autofluorescence System
|
N/A | |
Completed |
NCT00330382 -
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Recruiting |
NCT05237960 -
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
|
Phase 2 | |
Not yet recruiting |
NCT06256809 -
Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
|
||
Recruiting |
NCT04251845 -
Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
|
N/A | |
Terminated |
NCT04079491 -
Intra and Extra Oral Inspection of Oral Mucosa
|
||
Recruiting |
NCT00767442 -
Least Invasive Nonlinear Light Microscopy
|
N/A |